A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
NCT07634471Phase 2/3Recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 960 (estimated)
- Start date
- 22 Jun 2026
- Primary completion
- 23 Jul 2032 (estimated)
- Study completion
- 23 Jul 2035
- Last update posted
- 26 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Single
- Arms
- 3
Interventions
- MK-1045 Biological
- Rituximab Biological
- Rituximab biosimilar Biological
- Bendamustine Drug
- Cyclophosphamide Drug
- Vincristine Drug
- Prednisone Drug
- Prednisolone Drug
- Doxorubicin Hydrochloride Drug
Conditions and primary outcome
- Follicular Lymphoma
Primary outcome
Part 1: Number of Participants Who Experience an Adverse Event (AE) (Up to approximately 15 months); Part 1: Number of Participants Who Discontinue Study Treatment Due to an AE (Up to approximately 12 months); Part 1: Number of Participants Who Experience Dose Limiting Toxicity (DLT) (Up to approximately 36 days); Part 1: Complete Response (CR) Rate (Up to approximately 60 months); Part 2: Progression-Free Survival (PFS) (Up to approximately 63 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07634471.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07634471 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.